1. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–33.
2. Clark GM, Perez-Soler R, Siu L et al. Rash severity is predictive of increased survival with erlotinib hydrochloride [abstract 786]. Proc Am Soc Clin Oncol 2003; 22: 196.
3. Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract 817]. Proc Am Soc Clin Oncol 2003; 22.
4. West HL, Franklin WA, McCoy J et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24: 1807–13.
5. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238–47.
6. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
7. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006; 12: 6049–55.
8. Jackman DM, Yeap BY, Lindeman NI et al. Phase II clinical trial of chemotherapy-naive patients >70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 760–6.
9. Cohen EE, Kane MA, List MA et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418–24.
10. Soulieres D, Senzer NN, Vokes EE et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77–85.
11. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15: 785–92.
12. Gibson TB, Ranganathan A, Grothey A et al. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 29–31.
13. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2007; 25: 1960–6.
14. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22: 777–84.
15. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785–94.
16. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–56.
17. Tsao M-S, Sakurada A, Cutz J-C et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133–44.
18. Tsao M, Zhu C, Sakurada A et al. An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer [abstract 7005]. J Clin Oncol 2006; 24: 365s.
19. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12: 2166–71.
20. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64: 9139–43.
21. Etienne-Grimaldi MC, Pereira S, Magne N et al. Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. Ann Oncol 2005; 16: 934–41.
22. Mita AC, de Jonge M, Verweij J et al. Erlotinib (TarcevaR) "dosing-to-rash": preliminary results of a pilot phase II intra-patient dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) study of E in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract B118]. Proc AACR-NCI-EORTC 2005.
23. Rhee J, Oishi K, Garey J, Kim E. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin Colorectal Cancer 2005; 5: S101–6. Clin Cancer Res 2007; 13 (13): July 1 2007.

________________________________________________

B.Wacker, T.Nagrani, J.Weinberg, K.Witt, G.Clark, P.J.Cagnoni

OSI Pharmaceuticals, Boulder, Colorado